Form 4: Gilead Sciences Executive's Performance Share Vesting

Gilead Sciences' Chief Communications and Corporate Affairs Officer, Johanna Mercier, reported the acquisition of performance-vested shares and a related disposition for tax purposes.

Summary

• Johanna Mercier, Chief Communications and Corporate Affairs Officer of Gilead Sciences, Inc., reported transactions involving the company's common stock.
• On February 3, 2026, Mercier acquired 44,867 shares of common stock at a price of $0 per share.
• This acquisition represents specific tranches of performance share awards granted on March 10, 2023, and March 10, 2024.
• The performance vesting requirement for these awards was satisfied on February 3, 2026, following certification by the Compensation and Talent Committee.
• Shares from the March 10, 2024 grant will be issued upon meeting requisite continuing service requirements.
• On the same date, February 3, 2026, Mercier disposed of 24,800 shares of common stock at a price of $143.28 per share, likely for tax withholding related to the vesting.
• Following these transactions, Mercier's direct beneficial ownership stands at 123,288 shares of common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive indicator of management achieving performance goals, leading to the vesting of equity awards, which aligns executive incentives with company performance.

Positives

• The vesting of 44,867 performance share awards indicates that management, specifically Johanna Mercier, has met pre-defined performance goals set by the company's Compensation and Talent Committee.
• The satisfaction of performance vesting requirements aligns executive incentives with shareholder value creation.

Negatives

• A disposition of 24,800 shares occurred at $143.28 per share, which, while a common practice for tax withholding upon vesting, reduces the executive's direct beneficial ownership.

Future Outlook

Shares from the March 10, 2024 performance share award grant will not be issued until the requisite continuing service requirements are also met by the reporting person.

Management Comments

• The Compensation and Talent Committee of the Issuer's Board of Directors certified the attainment of performance goals for the performance share awards.

Industry Context

StockSavvy.ai notes that executive compensation often includes performance-based equity awards, aligning management incentives with shareholder value. The disposition for tax withholding is a common practice upon the vesting of such awards across various industries, including pharmaceuticals.

Comparison to Industry Standards

• StockSavvy.ai observes that performance share awards are a standard component of executive compensation packages across the pharmaceutical and biotechnology industries, similar to practices at companies like Pfizer, Merck, and Johnson & Johnson, where executive equity grants are tied to specific operational and financial milestones.
• The vesting of these shares indicates the achievement of pre-defined corporate objectives, a common benchmark for executive performance.

Corporate Governance

Related Party Transactions

• Acquisition of common stock by Chief Communications and Corporate Affairs Officer Johanna Mercier as part of performance share awards, and subsequent disposition for tax withholding, are transactions between the company and an executive.

Stakeholder Impact

• Shareholders benefit from management achieving performance goals, which is reflected in the vesting of performance-based equity.
• The reporting person, Johanna Mercier, receives compensation in the form of vested equity, aligning her interests with the company's long-term success.

Next Steps

• Issuance of shares from the March 10, 2024 grant upon meeting continuing service requirements.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation transactions (vesting of performance shares and subsequent tax-related disposition). It does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It confirms that management is meeting its performance targets, which is generally a neutral to slightly positive signal, but not enough to alter a fundamental investment thesis.

Keywords

Gilead Sciences, GILD, Form 4, Insider Transaction, Executive Compensation, Performance Shares, Stock Award, Equity Vesting